Dr. Figlin on remaining questions from KEYNOTE-564 trial of adjuvant pembrolizumab in RCC

Urology Times staff

Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, discusses remaining questions from the phase 3 KEYNOTE-564 trial, which was presented at the 2021 ASCO Annual Meeting (LBA5). The study findings showed that adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death versus placebo in patients with clear cell renal cell carcinoma. In the video, Figlin shares his expert observations on important questions that still remain, despite the positive results of the trial.